Ioanna Xagoraris

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: BMC CANCER. 2025;25(1):959
Toll-like receptor 9 (TLR9) expression correlates with cell of origin and predicts clinical outcome in diffuse large B-cell lymphoma
Abd Own S; Xagoraris I; Stathopoulou K; Wahlin BE; Ren W; Ghaderi M; Pan-Hammarstrom Q; Sander B; Smedby KE; Rassidakis G
Journal article: BLOOD. 2024;144:2999
NPM-ALK Oncoprotein Suppresses Anti-Tumor Immune Responses Partially through Cgas-Sting Pathway in ALK plus Anaplastic Large Cell Lymphoma
Xagoraris I; Yang Y; Trogrlic D; Mansson A; Plastira C; Leventaki V; Qian H; Lundqvist A; Rassidakis GZ
Article: NATURE COMMUNICATIONS. 2024;15(1):1752
Intestinal stroma guides monocyte differentiation to macrophages through GM-CSF
Kvedaraite E; Lourda M; Mouratidou N; Duking T; Padhi A; Moll K; Czarnewski P; Sinha I; Xagoraris I; Kokkinou E; Damdimopoulos A; Weigel W; Hartwig O; Santos TE; Soini T; Van Acker A; Rahkonen N; Tullberg MF; Ringqvist E; Buggert M; Jorns C; Lindforss U; Nordenvall C; Stamper CT; Unnersjoe-Jess D; Akber M; Nadisauskaite R; Jansson J; Vandamme N; Sorini C; Grundeken ME; Rolandsdotter H; Rassidakis G; Villablanca EJ; Idestroem M; Eulitz S; Arnell H; Mjoesberg J; Henter J-I; Svensson M
Article: CURRENT RESEARCH IN TRANSLATIONAL MEDICINE. 2023;71(3):103401
Establishment and characterization of a novel breast implant-associated anaplastic large cell lymphoma cell line and PDX model (BIA-XR1) with a unique KRAS mutation
Xagoraris I; Stathopoulou K; Aulerio RD; He M; Ketscher A; Jatta K; de Flon FH; Barbany G; Rosenquist R; Westerberg LS; Rassidakis GZ
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41 Suppl 2:318
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
Xagoraris I; Mulder T; Stathopoulou K; Xyderou P; Andersson M; Palma M; Rassidakis G
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41(S2):677
TREATMENT STRATEGIES AND PROGNOSTIC FACTORS FOR THE OUTCOME OF PATIENTS WITH HODGKIN LYMPHOMA EXPERIENCING VERY LATE RELAPSES AFTER CHEMOTHERAPY ± RADIOTHERAPY
Vassilakopoulos TP; Liaskas A; Rizzuto G; Symeonidis A; Palma M; Angelopoulou MK; Giatra C; Spanoudakis E; Oikonomopoulos P; Kondopidou FN; Dimou M; Musseti A; Xagoraris I; Siakantaris M; Panitsas F; Asimakopoulos J; Arapaki M; Chatzidimitriou C; Belia M; Sachanas S; Korkolopoulou P; Cabras A; Variami E; Panayotidis P; Bakiri M; Karmiris T; Rassidakis G; Corradini P; Pangalis GA; Viviani S
Article: HEMASPHERE. 2022;6(11):e794
Immune Biomarkers in the Peripheral Blood and Tumor Microenvironment of Classical Hodgkin Lymphoma Patients in Relation to Tumor Burden and Response to Treatment
Mulder TAA; Andersson MLL; Pena-Perez L; Heimersson K; Xagoraris I; Wahlin BE; Mansson R; Hansson L; Rassidakis G; Palma M
Journal article: HEMASPHERE. 2022;6(Suppl ):15-16
P032: Circulating immune biomarkers in classical Hodgkin lymphoma in relation to tumor burden and response to treatment.
Mulder TA; Andersson ML; Peña-Pérez L; Heimersson K; Xagoraris I; Wahlin BE; Månsson R; Hansson L; Rassidakis GZ; Palma M
Journal article: HEMASPHERE. 2022;6(Suppl ):23-24
P052: Targeting CSN5/JAB1 oncogene in classical Hodgkin Lymphoma (cHL)
Xagoraris I; Stathopoulou K; Renken S; Lundqvist A; Claret FX; Drakos E; Rassidakis GZ
Journal article: HEMASPHERE. 2022;6(Suppl ):53
P114: Very late relapses in patients with Hodgkin Lymphoma occuring ≥5 years after initial treament with chemotherapy ± radiotherapy: Treatment strategies and prognostic factors for the outcome
Vassilakopoulos TP; Liaskas A; Rizzuto G; Symeonidis A; Palma M; Angelopoulou MK; Giatra C; Kondopidou F; Dimou M; Musseti A; Xagoraris I; Siakantaris M; Verigou E; Panitsas F; Asimakopoulos J; Arapaki M; Chatzidimitriou C; Belia M; Sachanas S; Korkolopoulou P; Cabras A; Variamis E; Panayiotidis P; Bakiri M; Karmiris T; Rassidakis GZ; Corradini P; Pangalis G; Viviani S
Journal article: HEMASPHERE. 2022;6(Suppl ):24
P053: The cGAS-STING anti-tumor immune response pathway as a potential therapeutic target in classical Hodgkin Lymphoma (cHL)
Xagoraris I; Stathopoulou K; Xyderou P; Palma M; Drakos E; Vassilakopoulos TP; Rassidakis GZ
Journal article: HEMASPHERE. 2022;6(Suppl ):1168-1169
P1283: CIRCULATING IMMUNE CELLS IN CLASSICAL HODGKIN LYMPHOMA IN RELATION TO TUMOR BURDEN AND TREATMENT
Mulder TA; Andersson ML; Heimersson K; Xagoraris I; Wahlin BE; Rassidakis G; Hansson L; Palma M
Journal article: HEMASPHERE. 2022;6(Suppl ):2041-2042
PB2171: THE NOVEL CSN5/JAB1 INHIBITOR CSN5I-3 SUPPRESSES CELL GROWTH AND UPREGULATES GENE EXPRESSION OF TYPE-I INTERFERONS (IFN) IN ANAPLASTIC LARGE CELL LYMPHOMA (ALCL)
Xagoraris I; Kokaraki G; Stathopoulou K; Claret FX; Drakos E; Rassidakis GZ
Article: CANCERS. 2022;14(5):1186
Sting Is Commonly and Differentially Expressed in T- and Nk-Cell but Not B-Cell Non-Hodgkin Lymphomas
Xagoraris I; Farrajota Neves da Silva P; Kokaraki G; Stathopoulou K; Wahlin B; Osterborg A; Herold N; Ng S-B; Medeiros LJ; Drakos E; Sander B; Rassidakis GZ
Article: LEUKEMIA & LYMPHOMA. 2021;62(7):1563-1573
MDMX/MDM4 is highly expressed and contributes to cell growth and survival in anaplastic large cell lymphoma
Sinatkas V; Stathopoulou K; Xagoraris I; Ye J; Vyrla D; Atsaves V; Leventaki V; Medeiros LJ; Rassidakis GZ; Drakos E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;193(3):488-496
Expression of the novel tumour suppressor sterile alpha motif and HD domain-containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma
Xagoraris I; Vassilakopoulos TP; Drakos E; Angelopoulou MK; Panitsas F; Herold N; Medeiros LJ; Giakoumis X; Pangalis GA; Rassidakis GZ
Journal article: HEMASPHERE. 2019;3(S1):490-491
PS1082 PROGNOSTIC SIGNIFICANCE OF SAMHD1 EXPRESSION IN DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)
Xagoraris I; Herold N; Sander B; Smedby KE; Rassidakis G
Journal article: BLOOD. 2018;132(Supplement 1):4136
SAMHD1 Is Variably Expressed in Mantle Cell Lymphoma and Correlated to SOX11 but Not to Survival
Wasik AM; Marin E; Merrien M; de Matos Rodrigues J; Lord M; Xagoraris I; Christensson B; Rassidakis G; Jerkeman M; Ek S; Sander B
Article: BLOOD CANCER JOURNAL. 2018;8(11):98
Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens
Rassidakis GZ; Herold N; Myrberg IH; Tsesmetzis N; Rudd SG; Henter J-I; Schaller T; Ng S-B; Chng WJ; Yan B; Ng CH; Ravandi F; Andreeff M; Kantarjian HM; Medeiros LJ; Xagoraris I; Khoury JD

Alla övriga publikationer

Letter: LEUKEMIA. 2025;39(7):1787-1790
Sulforaphane promotes natural killer cell-mediated anti-tumor immune responses partially via cGAS-STING pathway in classical Hodgkin lymphoma
Xagoraris I; Yang Y; Bougka E; Trogrlic D; Xyderou P; Stathopoulou K; Herold N; Lundqvist A; Rassidakis GZ
Doctoral thesis: 2025
The role of SAMHD1 and cGAS-STING associated anti-tumor response mechanisms in lymphomas
Xagoraris I
Conference publication: HEMATOLOGICAL ONCOLOGY. 2023;41(S2):258
Activation of the Novel Tumor Suppressor SAMHD1 Inhibits Cell Growth and Induces Interferon‐beta (IFN‐β) Gene Expression in Classical Hodgkin Lymphoma (cHL)
Xagoraris I; Stathopoulou K; Nordentoft CAB; Xyderou P; Kurzay A; Lundqvist A; Herold N; Rassidakis G
Meeting abstract: BLOOD. 2022;140:3579-3580
Modulation of the CGAS-Sting Anti-Tumor Immune Response Pathway in an NF-KB-Dependent or -Independent Manner As a Potential Therapeutic Target in Classical Hodgkin Lymphoma (cHL)
Xagoraris I; Stathopoulou K; Xyderou P; Palma M; Drakos E; Vassilakopoulos TP; Rassidakis GZ
Conference publication: HEMASPHERE. 2022;6(Suppl ):1189-1190
P1304: THE NOVEL TUMOR SUPPRESSOR SAMHD1 CONTRIBUTES TO ANTI-TUMOR RESPONSES IN A CGAS-STING-DEPENDENT OR INDEPENDENT PATHWAY IN HODGKIN LYMPHOMA (HL)
Xagoraris I; Kokaraki G; Stathopoulou K; Xyderou P; Kurzay A; Herold N; Lundqvist A; Rassidakis GZ
Conference publication: LABORATORY INVESTIGATION. 2022;102(SUPPL 1):1040-1041
The Csn5/Jab1 Oncogene is Overexpressed and Suppresses Type 1 Interferon (IFN)-Associated Anti-Tumor Responses in Classical Hodgkin Lymphoma
Xagoraris I; Stathopoulou K; Kokaraki G; Claret F; Medeiros LJ; Elias D; Rassidakis GZ
Conference publication: MODERN PATHOLOGY. 2022;35(SUPPL 2):1040-1041
The Csn5/Jab1 Oncogene is Overexpressed and Suppresses Type 1 Interferon (IFN)-Associated Anti-Tumor Responses in Classical Hodgkin Lymphoma
Xagoraris I; Stathopoulou K; Kokaraki G; Claret F; Medeiros LJ; Elias D; Rassidakis GZ
Meeting abstract: BLOOD. 2021;138:1338
The NPM-ALK Oncogenic Kinase Suppresses CGAS-Sting-Associated Anti-Tumor Immune Responses through STAT3 Activation in Anaplastic Large Cell Lymphoma (ALCL)
Xagoraris I; Kokaraki G; Plastira C; Stathopoulou K; Leventaki V; Drakos E; Medeiros J; Osterborg A; Rassidakis GZ
Meeting abstract: BLOOD. 2021;138:3515
Mutations of the Novel Tumor Suppressor Gene SAMHD1 Are Frequent and Correlate with Decreased Protein Expression in Peripheral T-Cell Lymphomas (PTCL)
Kokaraki G; Xagoraris I; Da Silva PFN; Sutton LA; Falcao RM; de Souza JES; Osterborg A; Wirta V; Brandell RR; Rassidakis GZ
Letter: ANNALS OF HEMATOLOGY. 2020;99(3):649-651
Trametinib and Dabrafenib in histiocytic sarcoma transdifferentiated from chronic lymphocytic leukemia with a K-RAS and a unique BRAF mutation
Rassidakis GZ; Stromberg O; Xagoraris I; Jatta K; Sonnevi K
Conference publication: LABORATORY INVESTIGATION. 2019;99
The Tumor Suppressor SAMHD1 is a Novel Downstream Target of NPM-ALK Oncoprotein and MYC in Anaplastic Large Cell Lymphoma (ALCL)
Tsesmetzis N; Harold N; da Silva PFN; Hanna DK; Xagoraris I; Medeiros LJ; Drakos E; Leventaki V; Rassidakis GZ
Conference publication: MODERN PATHOLOGY. 2019;32
The Tumor Suppressor SAMHD1 is a Novel Downstream Target of NPM-ALK Oncoprotein and MYC in Anaplastic Large Cell Lymphoma (ALCL)
Tsesmetzis N; Harold N; da Silva PFN; Hanna DK; Xagoraris I; Medeiros LJ; Drakos E; Leventaki V; Rassidakis GZ
Meeting abstract: BLOOD. 2018;132
SAMHD1 Is Variably Expressed in Mantle Cell Lymphoma and Correlated to SOX11 but Not to Survival
Wasik AM; Marin E; Merrien M; Rodrigues JDM; Lord M; Xagoraris I; Christensson B; Rassidakis G; Jerkeman M; Ek S; Sander B
Meeting abstract: BLOOD. 2018;132:4130
The Novel Tumor Suppressor SAMHD1 Is Differentially Expressed and Partly Regulated By MYC in Peripheral T-Cell Lymphomas (PTCL)
Da Silva PFN; Tsesmetzis N; Xagoraris I; Wasik AM; Kokaraki G; Tzoras E; Osterborg A; Sander B; Herold N; Rassidakis G
Conference publication: BLOOD. 2017;130
MAPKAP1 (Sin1), a Key Component of the MTORC2 Complex, Confers Resistance to Sorafenib and Correlates with Adverse Clinical Outcomes in Acute Myeloid Leukemia
Khoury JD; Xagoraris I; Tsesmetzis N; Myrberg IHH; Olsen TK; Ng SB; Chng W-J; Yan B; Ng CH; Andreeff M; Medeiros LJ; Kantarjian HM; Herold N; Grander D; Rassidakis G
Conference publication: BLOOD. 2017;130
Low-Level SAMHD1 Expression in Acute Myeloid Leukemia Blasts Correlates with Favorable Outcome in Patients with Diploid Cytogenetics Treated with Cytarabine-Based Chemotherapy Regimens
Rassidakis G; Nikolas H; Myrberg IHH; Tsesmetzis N; Grander D; Kantarjian HM; Medeiros LJ; Xagoraris I; Khoury JD
Conference publication: BLOOD. 2017;130
Downregulation of the Tumor Suppressor SAMHD1 in Classical Hodgkin Lymphoma
Xagoraris I; Vassilakopoulos T; Herold N; Tsesmetzis N; Drakos E; Khoury JD; Rassidakis G
Conference publication: HAEMATOLOGICA. 2014;99:695
RAPID TRANSFORMATION OF FOLLICULAR LYMPHOMA, GRADE 1, ASSOCIATED WITH AN UNCOMMON C.796G>A PG266R MUTATION OF THE P53 GENE AND LOSS OF CD45 (LCA) EXPRESSION AT DIAGNOSIS
Kwiecinska A; Ghaderi M; Xagoraris I; Matolcsy A; Saft L; Otsterborg A; Rassidakis G
Conference publication: HAEMATOLOGICA. 2014;99:403
MYC ONCOGENE IS OVEREXPRESSED IN HODGKIN & REED STERNBERG CELLS (HRS) OF CLASSICAL HODGKIN LYMPHOMA AND CORRELATES WITH P53 EXPRESSION AND PROLIFERATION INDEX
Xagoraris I; Kwiecinska A; Ghaderi M; Tsioli P; Patsouris E; Drakos E; Rassidakis G

Anställningar

Postdoktorala Studier, Onkologi-Patologi, Karolinska Institutet, 2025-2028
Klinisk tjänst, ME Patologi & Cancerdiagnostik, Karolinska Universitetssjukhuset

Examina och utbildning

Medicine Doktorsexamen, Institutionen för onkologi-patologi, Karolinska Institutet, 2025

Gästforskning och resestipendier

Postdoktorala Studier, Karolinska Institutet, 2025-2028

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Gästforskning och resestipendier

Nyheter från KI

Kalenderhändelser från KI